GDF15 and neoplasm: Preclinical models further suggest that GDF15 inhibition might enhance the activity of bispecific T-cell engagers such as tebentafusp, which binds gp100 on GDF-15-secreting HLA-A2+ SK-MEL-5 melanoma cells, by restoring T-cell infiltration and improving tumor-specific immune responses [158].